CDK9-IN-7 |
| رقم الكتالوجGC35636 |
CDK9-IN-7 (المركب 21e) هو مثبط CDK9 / cyclin T انتقائي وفعال للغاية وفعال عن طريق الفم (IC50 = 11 نانومتر) ، والذي يظهر أكثر فاعلية على CDKs الأخرى (CDK4 / cyclinD = 148 نانومتر ؛ CDK6 / cyclinD = 145 نانومتر)يُظهر CDK9-IN-7 نشاطًا مضادًا للورم بدون سمية واضحةيستحث CDK9-IN-7 موت الخلايا المبرمج NSCLC ، ويوقف دورة الخلية في المرحلة G2 ، ويثبط خصائص الجذعية لـ NSCLC
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2369981-71-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1]. CDK9/cyclinT1|11 nM (IC50)|CDK4/cyclin D|148 nM (IC50)|CDK6/cyclinD|145 nM (IC50)
CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC50 values less than 0.5 µM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC50 value of 0.837 µM[1].
[1]. Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *